KYNB Kyntra Bio
Kyntra Bio earnings company data as of 4:48 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 9 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -3.38 | — |
| Rev | — | $100.0K | — |
Insider trades
Open-market buys and sales by KYNB's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $54K bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Thane Wettig CEOBuy$20K 2,800 shares at $7.09 +12% to stakeTraded May 14 Filed May 19
-
Thane Wettig CEOBuy$34K 3,700 shares at $9.12 +17% to stakeTraded Nov 13–17 Filed Nov 17, 2025
Also filed in the last 12 months, not counted as buying or selling: 8 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 22 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 3.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 1.01,2.03,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 3.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.03,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 8.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.